Dr. Giuseppe Nunnari

University of Catania, Italy

Email: [email protected]

Qualifications

2001  Ph.D., University of Catania, Italy

Publications (Selected)

1. Spampinato, S., Scuderi, G., Di Rosa, M., et al. (2026). Immune checkpoint landscape in CD4+ T cells stratifies HIV-infected individuals by clinical progression. Immunologic Research, 74(1), Article 44.
2. Scuderi, G., Spampinato, S., Di Rosa, M., et al. (2026). Region-Specific NRF2 Signaling in HIV-Associated Neurocognitive Disorders: A Transcriptomic and Computational Histology Study. Genes, 17(2), Article 195.
3. De Vito, A., Colpani, A., Moi, G., et al. (2025). Present and future of HIV pre-exposure prophylaxis: a narrative review. Future Virology, 20(10), 397–413.
4. Marino, A., Stracquadanio, S., Cosentino, F., et al. (2025). Phage to ESKAPE: Personalizing Therapy for MDR Infections-A Comprehensive Clinical Review. Pathogens, 14(10), Article 1011.
5. La Via, L., Maniaci, A., Lentini, M., et al. (2025). The Burden of Sepsis and Septic Shock in the Intensive Care Unit. Journal of Clinical Medicine, 14(19), Article 6691.
6. Marino, A., Augello, E., Bellanca, C. M., et al. (2025). Antibiotic Therapy Duration for Multidrug-Resistant Gram-Negative Bacterial Infections: An Evidence-Based Review. International Journal of Molecular Sciences, 26(14), Article 6905.
7. Bellanca, C. M., Polosa, S. P., Augello, E., et al. (2025). A scoping review about smoking, smoking cessation and their effects on anti-tuberculosis agents: insights into drug metabolisms, safety, and effectiveness. Frontiers in Pharmacology, 16, Article 1606150.
8. Marino, A., Maraolo, A. E., Mazzitelli, M., et al. (2025). Head-to-head: meropenem/vaborbactam versus ceftazidime/avibactam in ICUs patients with KPC-producing K. pneumoniae infections- results from a retrospective multicentre study. Infection, 53(6), 2645–2658.
9. De Vito, A., Geremia, N., Bavaro, D. F., et al. (2025). Comparing large language models for antibiotic prescribing in different clinical scenarios: which performs better?. Clinical Microbiology and Infection, 31(8), 1336–1342.
10. De Vito, A., Geremia, N., Bavaro, D. F., et al. (2025). Comparing large language models for antibiotic prescribing in different clinical scenarios: author's response. Clinical Microbiology and Infection, 31(8), 1410–1414.
11. Marino, A., Pipitone, G., Rullo, E. V., et al. (2025). Restoring Control: Real-World Success with Imipenem-Relebactam in Critical MDR Infections-A Multicenter Observational Study. Pathogens, 14(7), Article 685.
12. Franzò, A., Marino, A., Celesia, B. M., et al. (2025). Dirofilaria repens in the Spermatic Cord of a 5-Year-Old Boy: A Rare Pediatric Case in Italy. Tropical Medicine and Infectious Disease, 10(7), Article 184.
13. Spampinato, S., Rullo, E. V., Conti, G. N., et al. (2025). CD4/CD8 Ratio Increase in Female Living with HIV Switching to Cabotegravir-Rilpivirine: A Real-Life 24 Weeks Evaluation. Pathogens, 14(7), Article 633.
14. Geremia, N., Marino, A., De Vito, A., et al. (2025). Rare or Unusual Non-Fermenting Gram-Negative Bacteria: Therapeutic Approach and Antibiotic Treatment Options. Antibiotics, 14(3), Article 306.
15. Nunnari, G., & Calvari, S. (2025). Exploring Vision Transformers and Convolution Neural Networks for the Thermal Image Classification of Volcanic Activity. Applied Sciences, 15(5), Article 2604.
16. La Via, L., Marino, A., Cuttone, G., et al. (2025). Critical Care Pharmacology of Antiretroviral Therapy in Adults. European Journal of Drug Metabolism and Pharmacokinetics, 50(2), 105–118.
17. Calvari, S., & Nunnari, G. (2024). Reawakening of Voragine, the Oldest of Etna's Summit Craters: Insights from a Recurrent Episodic Eruptive Behavior. Remote Sensing, 16(22), Article 4278.
18. De Vito, A., Moi, G., Conti, G., et al. (2024). Real-life use of bictegravir/TAF/emtricitabine in a cohort of people with HIV with a high burden of comorbidities and a history of advanced HIV disease. Journal of the International AIDS Society, 27(Suppl 6), 142–143.
19. Nunnari, G., Spampinato, S., Conti, G. N., et al. (2024). PLWH treated with cabotegravir-rilpivirine have increased CD4/CD8 ratio and decreased CD8 T cells, as expression of lower inflammation, while maintaining virological suppression: a real-life 48 weeks analysis. Journal of the International AIDS Society, 27(Suppl 6), 100.
20. Colpani, A., De Vito, A., Marino, A., et al. (2024). Viro-Immunological Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide among Women Living with HIV: A 96-Week Post-Switch Analysis from the Real-Life SHiNe-SHiC Cohort. Biomedicines, 12(10), Article 2311.

profiles Details
https://www.medclin.unict.it/docenti/giuseppe.nunnari
https://www.researchgate.net/profile/Giuseppe-Nunnari-5


WOS ResearcherID: DME-4469-2022